$11.88+0.06 (+0.46%)
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally.
Neogen Corporation in the Healthcare sector is trading at $11.88 with a market capitalization of $2.6B. Wall Street consensus targets $13.33 (3 analysts), implying a +12.2% move over the next 12 months. The stock is currently near its 52-week high of $12.85, remaining 27.0% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $225.30M↑ | $211.20M↓ | $224.69M↑ | $209.19M↓ | $225.46M |
| Gross Profit | $107.80M↑ | $99.00M↓ | $106.68M↑ | $94.97M↑ | $92.86M |
| Operating Income | $3.10M↑ | -$3.30M↑ | -$5.38M↑ | -$16.09M↓ | -$13.25M |
| Net Income | -$11.30M↑ | -$17.00M↓ | -$15.92M↓ | $36.34M↑ | -$612.20M |
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test k...

Recent commentary around Neogen (NEOG) has focused on two pressure points for investors. Annual sales have declined for two years and returns on capital have shrunk, while a higher net debt to EBITDA ratio raises balance sheet sensitivity. The recent share price reflects that mixed picture. Neogen’s stock is up 29.5% on a 90 day share price return and 68.71% year to date, while the 1 year total shareholder return of 106.47% contrasts with a 3 year total shareholder return that has fallen...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Neogen stock has more than doubled over the past year, yet the broader valuation checks lean expensive rather than cheap, which may give investors pause after such a strong run. The share price has returned 106.5% over the past year, which sets a high bar for any further gains to be justified by fundamentals. Future growth in Neogen's revenue and cash generation can support the current share price, but any disappointment in execution or profitability may weigh heavily given the recent...

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.

NEOG shares gain 102.8% in a year as R&D investments, Food Safety growth and improving Animal Safety conditions fuel momentum despite key risks.